Key result
Review outlines current anticoagulation evidence and guidelines for managing VTE and AFib in active cancer.
Why the study?
Patients with cancer face high risks of thromboembolism and bleeding, and the role of DOACs alongside traditional anticoagulants needed synthesis into practical guidance.
This review summarizes current evidence and provides a practical approach to the use of DOACs, LMWH, and warfarin for managing VTE and AF in patients with active cancer.
DOACs may guide convenient anticoagulation in cancer VTE/AF; extends RCT data but leaves optimal regimens open pending dedicated trials.
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer.
No takes yet. Share an insight, caveat, or question.
Mosarla et al. (2019) conducted a review in Cancer with venous thromboembolism and atrial fibrillation. Anticoagulation strategies (DOACs, LMWH, warfarin) was evaluated. This review summarizes clinical trial data and guideline recommendations for the management of venous thromboembolism and atrial fibrillation in patients with active cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: